157 related articles for article (PubMed ID: 19139001)
1. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
[TBL] [Abstract][Full Text] [Related]
2. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
5. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
[TBL] [Abstract][Full Text] [Related]
6. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
[TBL] [Abstract][Full Text] [Related]
7. Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions.
Doyle KJ; McLaren CE; Shanks JE; Galus CM; Meyskens FL
Arch Otolaryngol Head Neck Surg; 2001 May; 127(5):553-8. PubMed ID: 11346432
[TBL] [Abstract][Full Text] [Related]
8. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
9. Dose-related alpha-difluoromethylornithine ototoxicity.
Croghan MK; Aickin MG; Meyskens FL
Am J Clin Oncol; 1991 Aug; 14(4):331-5. PubMed ID: 1862765
[TBL] [Abstract][Full Text] [Related]
10. Irreversible ototoxicity associated with difluoromethylornithine.
Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
12. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone.
Sporn MB; Hong WK
Cancer Prev Res (Phila); 2008 Jun; 1(1):9-11. PubMed ID: 19138930
[No Abstract] [Full Text] [Related]
13. Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
Chow CL; Havighurst T; Lozar T; Jones TD; Kim K; Bailey HH
Laryngoscope; 2023 Mar; 133(3):676-682. PubMed ID: 35620919
[TBL] [Abstract][Full Text] [Related]
14. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
[TBL] [Abstract][Full Text] [Related]
15. alpha-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results.
Pasic TR; Heisey D; Love RR
Arch Otolaryngol Head Neck Surg; 1997 Dec; 123(12):1281-6. PubMed ID: 9413354
[TBL] [Abstract][Full Text] [Related]
16. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
Lynch PM; Burke CA; Phillips R; Morris JS; Slack R; Wang X; Liu J; Patterson S; Sinicrope FA; Rodriguez-Bigas MA; Half E; Bulow S; Latchford A; Clark S; Ross WA; Malone B; Hasson H; Richmond E; Hawk E
Gut; 2016 Feb; 65(2):286-95. PubMed ID: 25792707
[TBL] [Abstract][Full Text] [Related]
17. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
Bailey HH; Kim K; Verma AK; Sielaff K; Larson PO; Snow S; Lenaghan T; Viner JL; Douglas J; Dreckschmidt NE; Hamielec M; Pomplun M; Sharata HH; Puchalsky D; Berg ER; Havighurst TC; Carbone PP
Cancer Prev Res (Phila); 2010 Jan; 3(1):35-47. PubMed ID: 20051371
[TBL] [Abstract][Full Text] [Related]
19. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.
Rial NS; Meyskens FL; Gerner EW
Essays Biochem; 2009 Nov; 46():111-24. PubMed ID: 20095973
[TBL] [Abstract][Full Text] [Related]
20. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
